Oncomine™ Comprehensive Assay Plus – Complete CGP test, now on the Genexus™ system.

Intro

Comprehensive Genomic Profiling (CGP) is at the heart of personalized medicine, enabling the identification of multiple genomic alterations in a single test. The Oncomine™ Comprehensive Assay Plus, powered by Ion Torrent™ technology, provides a streamlined approach to CGP, covering 517 unique genes across key cancer-related biomarkers.

What can you detect?

Comprehensive Biomarker Detection

The Oncomine™ Comprehensive Assay Plus enables detection of a wide range of genomic alterations critical for cancer diagnosis and treatment planning:

Single Nucleotide Variants (SNVs) & Indels – Small insertions and deletions across 517 genes
Copy Number Variations (CNVs) – Gene amplifications and deletions
Gene Fusions – Structural rearrangements including ALK, ROS1, RET, and NTRK fusions
Microsatellite Instability (MSI) – Comprehensive MSI status determination
Tumor Mutational Burden (TMB) – Assessment of overall mutation load
Loss of Heterozygosity (LOH) – Detection of allelic imbalance

Clinical Accuracy

99.26% Positive Percent Agreement (PPA) for SNVs
97.03% PPA for Indels
99.59% Overall accuracy across variant types

Fast, Automated Workflow

Running on the Genexus™ Integrated Sequencer, the entire workflow—from library preparation to variant reporting—is automated, reducing hands-on time to approximately 5 minutes per sample. Results are available in as little as one business day, enabling rapid clinical decision-making.

With a strong presence in Greece and abroad, we operate in fields that directly impact the health and well-being of people and societies.

We are a group of companies active in Biotechnology, Medical Technology, Analytical Instruments, and Diagnostic Applications.